Not Yet RecruitingEarly Phase 1NCT06979661

Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy

Primary Objective: Evaluate the role of ctDNA positivity in decision making for postoperative therapy for non-small cell lung cancer. The plan for postoperative therapy will be declared after pathology report review and before the ctDNA result. We will assess if ctDNA result changed the planned therapy. Secondary Objectives: Evaluate personalized postoperative Chemo/ICPI/Targeted Therapies/Radiation Therapy in clearing ctDNA Evaluate the disease-free survival (DFS) and overall survival (OS) of stage II/III lung cancer patients with postoperative ctDNA positive status Exploratory Objective: Evaluate radiomics features based on serial CT thoracic CT scans to determine if radiomic features can be associated with ctDNA positivity/negativity.

Checked against the public recordLast updated May 20, 2025 · Source: ClinicalTrials.gov

StatusNot Yet Recruiting
PhaseEarly Phase 1
U.S. locations1
SponsorRutgers, The State University of New Jersey
01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Early Phase 1
Sponsor
Rutgers, The State University of New Jersey
Interventions being studied
Diagnostic Test: Haystack™ ctDNA Assay
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: 1. Have provided signed informed consent for the trial 2. Aged ≥18 years at the time of informed consent 3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 4. Diagnosed with histologically confirmed Stage II-III NSCLC and undergone surgical resection of lung tumor 5. No active second cancers/malignancy 6. Patients that received preoperative therapy (including chemotherapy and immunotherapy or others) are eligible 7. Willing and able to comply with all aspects of the protocol 8. Standard of care therapy and methods as per institution and investigator discretion - Exclusion Criteria: Exclusion Criteria 1. Discontinued treatment due to a Grade 3 or higher AEs with chemotherapy or immunotherapy or targeted therapy agent 2. With a history of another primary malignancy within the past 2 years that is considered an active malignancy by the enrolling physician. 3. Have known active CNS metastases and/or carcinomatous meningitis. 4. Have a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis. 5. Have a history of interstitial lung disease. 6. Have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator. -

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Rutgers Cancer InstituteNew Brunswick, New Jersey

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 20, 2025. Always confirm current availability with the study team.

View original record ↗